According to a study published in the journal Scientific Reports, blood levels of specific molecules that promote or dampen inflammation can distinguish people with Sjögren’s disease from healthy individuals and offer clues about disease activity and gland involvement. Researchers in Italy found that patients with Sjögren’s show significantly higher blood concentrations of pro-inflammatory markers—specifically IL-15, MCP-1, TNFRII, and MMP-8—alongside lower levels of the anti-inflammatory molecule IL-1RII, compared with age-matched healthy controls.
Biomarkers Distinguish Sjögren’s Disease From Healthy Controls
Reliable biomarkers for diagnosing and monitoring Sjögren’s disease remain lacking, forcing clinicians to rely heavily on self-reactive antibodies and diverse symptom presentations. Because the autoimmune condition causes the immune system to attack moisture-producing glands while also affecting joints, lungs, kidneys, and nerves, predicting disease behavior is difficult. To address this gap, researchers analyzed blood samples from 40 people with Sjögren’s—consisting of 39 women with a mean age of 54.2 years—and 41 healthy women. Most patients, or 80%, reported dry mouth and dry eyes, while 45% experienced joint symptoms and 45% had systemic involvement beyond the salivary and tear glands.
Statistical analyses adjusted for potential influencing factors revealed that TNFRII and IL-1RII emerged as the strongest independent predictors of Sjögren’s. A predictive model incorporating these molecular levels demonstrated an area under the curve, or AUC, of 0.89. Higher AUC values indicate better performance in distinguishing affected individuals from healthy controls. Researchers noted that these findings align with prior evidence implicating TNF and IL-1/IL-1RII signaling pathways in the development of the condition.
Molecular Links to Clinical Features and Glandular Involvement
Beyond differentiating patients from healthy controls, several measured molecules associated closely with specific laboratory and clinical features of the disease. IL-15, a pro-inflammatory molecule previously identified as a potential therapeutic target, was significantly higher in patients with hypergammaglobulinemia, characterized by elevated antibody levels in the blood. The same molecule was significantly elevated in patients exhibiting a monoclonal component, reflecting the multiplication of a single antibody-producing immune B-cell.
MCP-1, a signaling molecule that attracts immune cells into inflamed tissues, showed a direct link to glandular disease severity. Higher blood MCP-1 levels associated significantly with higher focus score values—a measure of immune cell clusters in salivary gland tissue that form a hallmark of Sjögren’s—as well as more severe dry eyes and mouth. Conversely, while overall patient levels of IL-1RII were lower than those of controls, individuals testing positive for self-reactive antibodies against the La, or SSB, protein displayed significantly higher IL-1RII levels than those testing negative.
Pro Tip: Understanding the specific molecular profile of an autoimmune condition can help clinicians better assess immune dysregulation, though authors of the Scientific Reports study emphasize that larger prospective trials are required before these markers enter routine clinical practice.
Study Limitations and Future Validation Needs
Despite identifying novel associations, such as the link between Sjögren’s and the tissue-remodeling protein MMP-8, the study authors acknowledged several important limitations. The research relied on a small sample size from a single medical center, and samples were collected at a single point in time. This cross-sectional design cannot determine whether the identified markers predict disease progression or change in response to treatment.
“Further prospective studies in larger and independent [groups of patients] are warranted to validate these findings and to clarify the potential clinical utility of these biomarkers for disease stratification and monitoring,” the researchers wrote. Nevertheless, the identification of TNFRII, IL-1RII, and MMP-8 as variables strongly associated with disease-related immune dysregulation provides a foundation for future biomarker development.
Did You Know? Sjögren’s disease primarily attacks moisture-producing glands, leading to chronic dry eyes and dry mouth, but it can also impact the skin, blood vessels, and peripheral nerves.
Frequently Asked Questions About Sjögren’s Biomarkers
What molecules were found at higher levels in Sjögren’s patients?
According to the study published in Scientific Reports, patients showed significantly higher blood levels of the pro-inflammatory molecules IL-15, MCP-1, TNFRII, and MMP-8 compared with healthy controls.
Which molecules are the strongest predictors of the disease?
TNFRII and IL-1RII emerged as the strongest independent predictors of Sjögren’s disease in adjusted statistical models, yielding an area under the curve value of 0.89.
Are these blood markers currently used for routine diagnosis?
No. While these molecules offer clues about disease activity and immune dysregulation, researchers stress that larger prospective studies are needed to validate their clinical utility before they can be used for routine disease monitoring and stratification.
What are your thoughts on the development of new diagnostic blood markers for autoimmune conditions? Share your perspective in the comments below, or subscribe to our newsletter for ongoing updates on immunology research.
Keep reading